**Core Concept**
The combination of anakinra and infliximab in rheumatoid arthritis patients involves the use of biologic agents that target different pathways of the immune system. Anakinra is an interleukin-1 (IL-1) receptor antagonist, while infliximab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor.

**Why the Correct Answer is Right**
The combination of anakinra and infliximab is not recommended because it can increase the risk of serious infections and other adverse effects. This is due to the overlapping mechanisms of action, as both drugs modulate the immune response by inhibiting pro-inflammatory cytokines. The combination may lead to an increased risk of neutropenia, anemia, and other hematologic abnormalities. Additionally, the use of two biologic agents may increase the risk of opportunistic infections, such as sepsis, tuberculosis, and other infections.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because there is no evidence to support the use of combination therapy with anakinra and infliximab as a standard treatment approach for rheumatoid arthritis.
* **Option B:** This option is incorrect because the combination of anakinra and infliximab is not recommended due to the increased risk of adverse effects, not because it is ineffective in treating rheumatoid arthritis.
* **Option C:** This option is incorrect because the combination of anakinra and infliximab is not typically used to treat rheumatoid arthritis in patients with a history of malignancy.

**Clinical Pearl / High-Yield Fact**
When using biologic agents in the treatment of rheumatoid arthritis, it is essential to carefully evaluate the potential risks and benefits of combination therapy and to consider the patient's medical history and comorbidities.

**Correct Answer:** D.